Literature DB >> 8063247

p53 alterations in uterine leiomyosarcomas versus leiomyomas.

S de Vos1, S P Wilczynski, M Fleischhacker, P Koeffler.   

Abstract

Leiomyoma is the most common benign smooth muscle tumor. Although rare in other organs, it is frequent in the uterus, occurring in nearly 40% of women over 50 years of age. These benign tumors rarely undergo malignant transformation. The incidence of leiomyosarcomas in uterine leiomyomas is estimated to be between 0.13 and 0.29%. Little is known of the genetic abnormalities leading to this neoplasia. Loss of p53 function has been implicated in the pathogenesis of many human tumors. We evaluated eight leiomyosarcomas and eight leiomyomas for alterations in exons 5-8 of p53, which are the mutational hotspots for this gene in human malignancies. Genomic DNA of the samples was studied by single-strand conformation polymorphism (SSCP) analysis and positive samples were analyzed by direct sequencing of PCR-amplified products. Each exon was studied individually, and positive controls were used for each exon. Three alterations in a total of eight leiomyosarcoma samples were found; the changes were point mutations (exon 5, codon 165; exon 8, codon 275; exon 8, codon 266). No alterations of p53 could be demonstrated in the eight leiomyoma samples. Our results show for the first time that p53 mutations are frequent in leiomyosarcomas, and one distinguishing difference between benign leiomyomas and some malignant leiomyosarcomas is the acquisition of a p53 mutation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063247     DOI: 10.1006/gyno.1994.1194

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.

Authors:  Weiwei Shan; Patricia Y Akinfenwa; Kari B Savannah; Nonna Kolomeyevskaya; Rudolfo Laucirica; Dafydd G Thomas; Kunle Odunsi; Chad J Creighton; Dina C Lev; Matthew L Anderson
Journal:  Clin Cancer Res       Date:  2012-04-25       Impact factor: 12.531

2.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

3.  Pleomorphic leiomyosarcoma of the adrenal gland with osteoclast-like giant cells.

Authors:  Fernando A Candanedo-González; Teresa Vela Chávez; Arturo Cérbulo-Vázquez
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Authors:  Kari J Brewer Savannah; Elizabeth G Demicco; Kristelle Lusby; Markus Ph Ghadimi; Roman Belousov; Eric Young; Yiqun Zhang; Kai-Lieh Huang; Alexander J Lazar; Kelly K Hunt; Raphael E Pollock; Chad J Creighton; Matthew L Anderson; Dina Lev
Journal:  Clin Cancer Res       Date:  2012-07-20       Impact factor: 12.531

5.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

6.  Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma.

Authors:  Jasmine H Francis; Ruth A Kleinerman; Johanna M Seddon; David H Abramson
Journal:  Gynecol Oncol       Date:  2011-10-23       Impact factor: 5.482

7.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 8.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

9.  Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Authors:  Katherine V Clark-Knowles; Mary K Senterman; Olga Collins; Barbara C Vanderhyden
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

10.  Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases.

Authors:  Jennifer Hung; Susan M Hiniker; David R Lucas; Kent A Griffith; Jonathan B McHugh; Amichay Meirovitz; Dafydd G Thomas; Rashmi Chugh; Joseph M Herman
Journal:  Sarcoma       Date:  2013-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.